Naftifine


Full Prescribing Info
Dosage/Direction for Use

Topical/Cutaneous
Skin fungal infections
Adult: As hydrochloride: Apply sufficient amount of 1% cream once daily or 1% gel bid, morning and evening. Treatment duration: Tinea cruris and tinea corporis: 2-4 wk; tinea pedis: 4-6 wk; severe infections: May require prolonged treatment.
Contraindications
Hypersensitivity.
Special Precautions
Avoid contact with eyes, nose, mouth and other mucous membranes. Avoid use of occlusive dressings or wrappings. Discontinue use if irritation occurs. Pregnancy and lactation.
Adverse Reactions
Burning, stinging, dryness, redness, pruritus, local irritation, rash, skin tenderness.
Action
Naftifine is a synthetic allylamine antifungal that selectively inhibits the enzyme squalene monooxygenase resulting in reduced synthesis of the primary sterol, ergosterol, within the fungal membrane. It appears to have both fungicidal and fungistatic activity.
Absorption: Approx 3-6 % absorbed systemically after application of cream or gel; sufficient concentrations retained in the upper skin layers to inhibit the growth of dermatophytes at this site for 24 hr.
Distribution: Distributed into the milk of rats (topical).
Metabolism: Metabolised to at least 3 metabolites via oxidation of the phenyl and naphthyl rings and by N-dealkylation.
Excretion: Via urine and faeces (as unchanged drug and/or metabolites). Half-life: Approx 2-3 days (topical).
Storage
Topical/Cutaneous: Cream: Store below 30°C (86°F). Gel: Store at room temperature.
ATC Classification
D01AE22 - naftifine ; Belongs to the class of other antifungals for topical use.
Disclaimer: This information is independently developed by CIMS based on naftifine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in